Altitude Group PLC (GB00B0LSFV82)
Summary
GB00B0LSFV82 Chart
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Altitude Group PLC (GB00B0LSFV82) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Altitude Group PLC ever had a stock split?
Altitude Group PLC Profile
| Biotechnology Industry | Healthcare Sector | Jerome Benedict Durso CEO | XSTU Exchange | US02155H2004 ISIN |
| US Country | 57 Employees | 14 Sep 2018 Last Dividend | 14 Sep 2018 Last Split | 6 Oct 2005 IPO Date |
Overview
Altimmune, Inc., originally established under the name Vaxin Inc., is a biopharmaceutical company that has been at the forefront of clinical stage development since its foundation in 1997. With a strategic focus geared towards addressing obesity and liver diseases, the company has become a key player in the field. Having rebranded to Altimmune, Inc. in September 2015, the organization continues to advance its mission from its headquarters in Gaithersburg, Maryland. By leveraging its expertise in biopharmaceuticals, Altimmune is dedicated to bringing innovative treatments to patients battling these complex health issues.
Products and Services
- Pemvidutide
Pemvidutide stands as Altimmune's leading product candidate, a pioneering GLP-1/glucagon dual receptor agonist tailored for obesity treatment. This novel therapy is currently undergoing a Phase 2 clinical trial, showcasing its potential in combatting obesity and the metabolic dysfunctions associated with steatohepatitis. By targeting two critical pathways involved in metabolism, Pemvidutide exemplifies Altimmune's commitment to addressing the growing global obesity epidemic with science-driven solutions.
- HepTcell
Another significant advancement from Altimmune is HepTcell, an innovative immunotherapeutic aimed at treating chronic hepatitis B virus (HBV) infection. Currently in a Phase 2 clinical trial, HepTcell embodies Altimmune's strategic effort to combat viral liver diseases by harnessing the body's immune response. Through this approach, HepTcell offers hope to patients suffering from chronic HBV, showcasing Altimmune's dedication to tackling infectious diseases with cutting-edge biopharmaceutical technologies.
